A new glaucoma drop called latanoprost shows visual preservation over a 2 year study.- MDA
Larry Hand
Latanoprost eye drops were shown to preserve visual field in patients with open-angle glaucoma in a relatively short time, and the benefits grew with longer treatment, according to a study published online December 18 in the Lancet.
The study is the first randomized placebo-controlled trial to evaluate the vision-preserving effect of an intraocular pressure-lowering drug, write David F. Garway-Heath, MD, from the National Institute for Health Research Biomedical Research Centre, London, United Kingdom, and colleagues. The authors randomly assigned 516 patients newly diagnosed with open-angle glaucoma at ten UK centers to receive either 0.005% latanoprost or placebo eye drops once daily between December 1, 2006, and March 16, 2010.
They found that patients in the treatment group experienced significantly longer visual field preservation compared with those in the placebo group (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.28 – 0.69; P = .0003).
“The results of the [United Kingdom Glaucoma Treatment Study] give clinicians greater confidence in recommending the treatment to patients because there is now top-level evidence for the extent to which intraocular pressure-lowering with latanoprost preserves vision compared to placebo,” Dr Garway-Health told Medscape Medical News. “As there was a placebo arm, it was possible to follow the natural, untreated, history of the condition.”
The researchers conducted visual field testing, intraocular pressure measurement, and imaging during 11 scheduled visits over the course of 24 months during the triple-masked trial……..
Read more: http://www.medscape.com/viewarticle/837180
source: Medscape  Image: guthrieeyecare.com

On